Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.17
PKI's Cash to Debt is ranked lower than
89% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.75 vs. PKI: 0.17 )
Ranked among companies with meaningful Cash to Debt only.
PKI' s 10-Year Cash to Debt Range
Min: 0.09  Med: 0.33 Max: 2.06
Current: 0.17
0.09
2.06
Equity to Asset 0.51
PKI's Equity to Asset is ranked lower than
67% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. PKI: 0.51 )
Ranked among companies with meaningful Equity to Asset only.
PKI' s 10-Year Equity to Asset Range
Min: 0.24  Med: 0.50 Max: 0.63
Current: 0.51
0.24
0.63
Interest Coverage 5.81
PKI's Interest Coverage is ranked lower than
85% of the 95 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1009.34 vs. PKI: 5.81 )
Ranked among companies with meaningful Interest Coverage only.
PKI' s 10-Year Interest Coverage Range
Min: 2.15  Med: 5.81 Max: 16.75
Current: 5.81
2.15
16.75
F-Score: 5
Z-Score: 3.27
M-Score: -2.63
WACC vs ROIC
3.06%
7.38%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 9.69
PKI's Operating margin (%) is ranked higher than
73% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.26 vs. PKI: 9.69 )
Ranked among companies with meaningful Operating margin (%) only.
PKI' s 10-Year Operating margin (%) Range
Min: 1.62  Med: 8.56 Max: 10.86
Current: 9.69
1.62
10.86
Net-margin (%) 7.34
PKI's Net-margin (%) is ranked higher than
76% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.79 vs. PKI: 7.34 )
Ranked among companies with meaningful Net-margin (%) only.
PKI' s 10-Year Net-margin (%) Range
Min: -10.1  Med: 5.99 Max: 22.94
Current: 7.34
-10.1
22.94
ROE (%) 7.99
PKI's ROE (%) is ranked higher than
70% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.52 vs. PKI: 7.99 )
Ranked among companies with meaningful ROE (%) only.
PKI' s 10-Year ROE (%) Range
Min: -11.62  Med: 8.04 Max: 32.47
Current: 7.99
-11.62
32.47
ROA (%) 4.11
PKI's ROA (%) is ranked higher than
72% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.89 vs. PKI: 4.11 )
Ranked among companies with meaningful ROA (%) only.
PKI' s 10-Year ROA (%) Range
Min: -5.23  Med: 4.26 Max: 12.48
Current: 4.11
-5.23
12.48
ROC (Joel Greenblatt) (%) 45.26
PKI's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.36 vs. PKI: 45.26 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PKI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 4.35  Med: 36.06 Max: 72.5
Current: 45.26
4.35
72.5
Revenue Growth (3Y)(%) 5.30
PKI's Revenue Growth (3Y)(%) is ranked lower than
53% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. PKI: 5.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PKI' s 10-Year Revenue Growth (3Y)(%) Range
Min: -12.3  Med: 1.10 Max: 17.9
Current: 5.3
-12.3
17.9
EBITDA Growth (3Y)(%) 17.30
PKI's EBITDA Growth (3Y)(%) is ranked higher than
76% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. PKI: 17.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PKI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -20.9  Med: 3.90 Max: 35.2
Current: 17.3
-20.9
35.2
EPS Growth (3Y)(%) 421.70
PKI's EPS Growth (3Y)(%) is ranked higher than
99% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. PKI: 421.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PKI' s 10-Year EPS Growth (3Y)(%) Range
Min: -79  Med: 9.30 Max: 421.7
Current: 421.7
-79
421.7
» PKI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

PKI Guru Trades in Q3 2014

Joel Greenblatt 137,475 sh (+149.15%)
PRIMECAP Management 2,254,111 sh (+6.51%)
Ken Fisher 614,529 sh (+1.09%)
Vanguard Health Care Fund 1,441,400 sh (unchged)
Chuck Royce 3,540,320 sh (unchged)
Jim Simons Sold Out
Columbia Wanger Sold Out
RS Investment Management 393,514 sh (-0.09%)
» More
Q4 2014

PKI Guru Trades in Q4 2014

Jim Simons 248,000 sh (New)
Joel Greenblatt 610,891 sh (+344.37%)
PRIMECAP Management 3,260,285 sh (+44.64%)
Vanguard Health Care Fund 1,441,400 sh (unchged)
RS Investment Management Sold Out
Ken Fisher 611,262 sh (-0.53%)
Chuck Royce 2,778,200 sh (-21.53%)
» More
Q1 2015

PKI Guru Trades in Q1 2015

Steven Cohen 18,400 sh (New)
PRIMECAP Management 3,462,295 sh (+6.20%)
Ken Fisher 626,715 sh (+2.53%)
Vanguard Health Care Fund 1,441,400 sh (unchged)
Joel Greenblatt Sold Out
Chuck Royce 2,740,100 sh (-1.37%)
Jim Simons 138,500 sh (-44.15%)
» More
Q2 2015

PKI Guru Trades in Q2 2015

Ken Fisher 646,420 sh (+3.14%)
» More
» Details

Insider Trades

Latest Guru Trades with PKI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 35.80
PKI's P/E(ttm) is ranked lower than
56% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.10 vs. PKI: 35.80 )
Ranked among companies with meaningful P/E(ttm) only.
PKI' s 10-Year P/E(ttm) Range
Min: 5.27  Med: 26.87 Max: 3956.25
Current: 35.8
5.27
3956.25
Forward P/E 17.83
PKI's Forward P/E is ranked higher than
64% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.00 vs. PKI: 17.83 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 34.40
PKI's PE(NRI) is ranked lower than
54% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.10 vs. PKI: 34.40 )
Ranked among companies with meaningful PE(NRI) only.
PKI' s 10-Year PE(NRI) Range
Min: 11.52  Med: 28.38 Max: 2724
Current: 34.4
11.52
2724
P/B 2.85
PKI's P/B is ranked higher than
59% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.58 vs. PKI: 2.85 )
Ranked among companies with meaningful P/B only.
PKI' s 10-Year P/B Range
Min: 0.88  Med: 1.80 Max: 2.98
Current: 2.85
0.88
2.98
P/S 2.62
PKI's P/S is ranked higher than
54% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.95 vs. PKI: 2.62 )
Ranked among companies with meaningful P/S only.
PKI' s 10-Year P/S Range
Min: 0.72  Med: 1.77 Max: 2.76
Current: 2.62
0.72
2.76
PFCF 26.35
PKI's PFCF is ranked higher than
62% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.48 vs. PKI: 26.35 )
Ranked among companies with meaningful PFCF only.
PKI' s 10-Year PFCF Range
Min: 7.78  Med: 20.04 Max: 92.3
Current: 26.35
7.78
92.3
POCF 23.35
PKI's POCF is ranked higher than
50% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.03 vs. PKI: 23.35 )
Ranked among companies with meaningful POCF only.
PKI' s 10-Year POCF Range
Min: 6.3  Med: 16.46 Max: 42.44
Current: 23.35
6.3
42.44
EV-to-EBIT 31.32
PKI's EV-to-EBIT is ranked lower than
70% of the 89 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.73 vs. PKI: 31.32 )
Ranked among companies with meaningful EV-to-EBIT only.
PKI' s 10-Year EV-to-EBIT Range
Min: 9.4  Med: 20.40 Max: 57.1
Current: 31.32
9.4
57.1
PEG 3.44
PKI's PEG is ranked lower than
51% of the 37 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. PKI: 3.44 )
Ranked among companies with meaningful PEG only.
PKI' s 10-Year PEG Range
Min: 0.58  Med: 2.82 Max: 46.41
Current: 3.44
0.58
46.41
Shiller P/E 37.31
PKI's Shiller P/E is ranked lower than
60% of the 53 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.91 vs. PKI: 37.31 )
Ranked among companies with meaningful Shiller P/E only.
PKI' s 10-Year Shiller P/E Range
Min: 10.11  Med: 26.97 Max: 41.14
Current: 37.31
10.11
41.14
Current Ratio 1.86
PKI's Current Ratio is ranked lower than
69% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. PKI: 1.86 )
Ranked among companies with meaningful Current Ratio only.
PKI' s 10-Year Current Ratio Range
Min: 0.74  Med: 1.66 Max: 2.13
Current: 1.86
0.74
2.13
Quick Ratio 1.33
PKI's Quick Ratio is ranked lower than
76% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.31 vs. PKI: 1.33 )
Ranked among companies with meaningful Quick Ratio only.
PKI' s 10-Year Quick Ratio Range
Min: 0.54  Med: 1.22 Max: 1.7
Current: 1.33
0.54
1.7
Days Inventory 84.04
PKI's Days Inventory is ranked lower than
53% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.75 vs. PKI: 84.04 )
Ranked among companies with meaningful Days Inventory only.
PKI' s 10-Year Days Inventory Range
Min: 42.34  Med: 77.38 Max: 110.09
Current: 84.04
42.34
110.09
Days Sales Outstanding 67.88
PKI's Days Sales Outstanding is ranked lower than
52% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.45 vs. PKI: 67.88 )
Ranked among companies with meaningful Days Sales Outstanding only.
PKI' s 10-Year Days Sales Outstanding Range
Min: 54.48  Med: 73.30 Max: 96.02
Current: 67.88
54.48
96.02

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.55
PKI's Dividend Yield is ranked lower than
83% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.43 vs. PKI: 0.55 )
Ranked among companies with meaningful Dividend Yield only.
PKI' s 10-Year Dividend Yield Range
Min: 0.52  Med: 1.13 Max: 2.43
Current: 0.55
0.52
2.43
Dividend Payout 0.19
PKI's Dividend Payout is ranked higher than
83% of the 47 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.34 vs. PKI: 0.19 )
Ranked among companies with meaningful Dividend Payout only.
PKI' s 10-Year Dividend Payout Range
Min: 0.03  Med: 0.30 Max: 3.5
Current: 0.19
0.03
3.5
Yield on cost (5-Year) 0.55
PKI's Yield on cost (5-Year) is ranked lower than
84% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.55 vs. PKI: 0.55 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
PKI' s 10-Year Yield on cost (5-Year) Range
Min: 0.52  Med: 1.13 Max: 2.43
Current: 0.55
0.52
2.43

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.75
PKI's Price/Projected FCF is ranked higher than
60% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. PKI: 1.75 )
Ranked among companies with meaningful Price/Projected FCF only.
PKI' s 10-Year Price/Projected FCF Range
Min: 0.52  Med: 1.34 Max: 131.1
Current: 1.75
0.52
131.1
Price/DCF (Earnings Based) 4.86
PKI's Price/DCF (Earnings Based) is ranked lower than
85% of the 13 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.91 vs. PKI: 4.86 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.46
PKI's Price/Median PS Value is ranked lower than
76% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. PKI: 1.46 )
Ranked among companies with meaningful Price/Median PS Value only.
PKI' s 10-Year Price/Median PS Value Range
Min: 0.3  Med: 0.92 Max: 1.91
Current: 1.46
0.3
1.91
Price/Peter Lynch Fair Value 1.71
PKI's Price/Peter Lynch Fair Value is ranked higher than
64% of the 28 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.02 vs. PKI: 1.71 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
PKI' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.74  Med: 3.04 Max: 16.36
Current: 1.71
0.74
16.36
Earnings Yield (Greenblatt) (%) 3.16
PKI's Earnings Yield (Greenblatt) (%) is ranked higher than
65% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. PKI: 3.16 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PKI' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.8  Med: 4.90 Max: 10.6
Current: 3.16
1.8
10.6
Forward Rate of Return (Yacktman) (%) 22.85
PKI's Forward Rate of Return (Yacktman) (%) is ranked higher than
85% of the 53 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.12 vs. PKI: 22.85 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
PKI' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -10.3  Med: 10.00 Max: 43.7
Current: 22.85
-10.3
43.7

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:PKN.Germany,
PerkinElmer Inc is a Massachusetts corporation, founded in 1947. The Company provides products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. Through its advanced technologies, solutions, and services, it addresses critical issues that help to improve the health and safety of people and their environment. The Company reports its business in two segments: Human Health and Environmental Health. Its Human Health segment concentrates on developing diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. Within the Human Health segment, it serves both the Diagnostics and Research Markets. In Diagnostics Markets it provides early detection for genetic disorders from pre-conception to early childhood, as well as digital x-ray flat panel detectors and infectious disease testing for the diagnostics market. In the Research market, it provides suite of solutions including reagents, liquid handling and detection and imaging technologies that enable researchers to improve the drug discovery process. Its main products for Human Health applications includes DELFIA Xpress screening platform, NeoGram MS/MS AAAC in vitro diagnostic kit, NeoBase Non-derivatized MS/MS kit, Specimen Gate informatics data management solution, XRD family of amorphous silicon digital x-ray flat panel detectors, Opera high content screening system and Operetta high content imaging system, UltraVIEW VoX 3D live cell imaging system and Asset Genius, an informatics-based business intelligence solution. Its Environmental Health segment provides products, services and solutions to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets. Its main products Environmental Health applications includes Clarus series of gas chromatographs, Flexar series of liquid chromatography and mass spectrometry instruments and LAMBDA UV/Vis series. The Company's main brands include AlphaLISA, AlphaScreen, Asset Genius, AutoDELFIA, BACS-on-Beads, BoBs, cell::explorer, Chem3D, ChemBioOffice, ChemDraw, Columbus, Datalytix, Dexela CMOS FPDs, Elsevier's Reaxys, EnLite, Ensemble for Biology, Ensemble for Chemistry and Ensemble for QA/QC. Its customers include pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors and government agencies. It competes with foreign and domestic organizations, which produce a comprehensive array of goods and services. The Company's operations are subject to various foreign, federal, state and local safety laws.
» More Articles for PKI

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Family Dollar Stores Inc, Texas Instruments Inc, Mylan Inc, and PerkinEl Feb 08 2015 
Parkland Fuel Corporation Announces October 2014 Dividend Oct 15 2014 
Vanguard Health Care Fund Gains 27%, Buys 4 New Stocks Jul 31 2013 
The Best Dividends on April 18, 2012 Apr 18 2012 
PerkinElmer Inc. Reports Operating Results (10-K) Mar 01 2011 
PerkinElmer Inc. Reports Operating Results (10-Q) Nov 10 2010 
PerkinElmer Inc. Reports Operating Results (10-Q) Aug 10 2010 
PerkinElmer Inc. Reports Operating Results (10-Q) May 13 2010 
PerkinElmer Inc. (PKI) Chairman, President & CEO Robert F Friel sells 150,000 Shares Dec 17 2009 
PerkinElmer Acquires Leading Diagnostics Company in China Sep 08 2009 

More From Other Websites
PerkinElmer reports surprise rise in Q2 revenue Jul 30 2015
PerkinElmer Announces Financial Results for the Second Quarter of 2015 Jul 30 2015
Q2 2015 PerkinElmer Inc Earnings Release - After Market Close Jul 30 2015
Is PerkinElmer (PKI) Poised to Beat Q2 Earnings Estimates? - Analyst Blog Jul 27 2015
PerkinElmer Board Declares Quarterly Dividend Jul 23 2015
Edinburgh Partners Continues To Trim Top Picks Amid 2015 Struggles Jul 14 2015
PerkinElmer to Hold Earnings Call on Thursday, July 30, 2015 Jul 06 2015
AMRI continues to build Buffalo partnerships Jun 19 2015
AMRI and PerkinElmer Announce Drug Discovery Collaboration as part of the Buffalo Medical Innovation... Jun 17 2015
These Stocks Look Overvalued Jun 17 2015
PerkinElmer to Present at Goldman Sachs Global Healthcare Conference May 26 2015
PerkinElmer Hits 52-Week High on Strong Q1, Favorable View - Analyst Blog May 21 2015
10-Q for PerkinElmer, Inc. (United States) May 07 2015
PerkinElmer to Present at UBS Global Healthcare Conference May 07 2015
PERKINELMER INC Files SEC form 10-Q, Quarterly Report May 05 2015
PerkinElmer to Present at Bank of America Merrill Lynch 2015 Healthcare Conference May 04 2015
PerkinElmer Beats Q1 Earnings, Misses Revenue; Guides Up - Analyst Blog May 01 2015
PerkinElmer (PKI) Earnings Report: Q1 2015 Conference Call Transcript May 01 2015
Coverage initiated on PerkinElmer by Mizuho May 01 2015
PERKINELMER INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK